BioMarin Licenses Summit’s Muscular Dystrophy Programme
By Taskin Ahmed
Pharma Deals Review: Vol 2008 Issue 98 (Table of Contents)
Published: 22 Jul-2008
DOI: 10.3833/pdr.v2008.i98.155 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
BioMarin Pharmaceutical and Summit Corporation plc entered into an exclusive worldwide licensing agreement for Summit’s preclinical candidate, SMT C1100, and all follow-on molecules for the treatment of Duchenne muscular dystrophy...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018